Recent Updates
Recently added Catalysts
JSPR Negative Sentiment Score: 25/100

Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – JSPR

Key Takeaway: Jasper Therapeutics, Inc. is currently facing a class action lawsuit for alleged violations of securities laws, specifically regarding misleading statements made to investors. The DJS Law Group is reaching out to shareholders who purchased stock during the specified class period. Claims suggest that the company's manufacturing partners did not comply with applicable regulations, which jeopardized the integrity of its clinical trials. Shareholders are encouraged to contact the firm to discuss their rights and potential participation in the case.

Market Sentiment Analysis

CONCERNS & RISKS

  • The Company is facing a class action lawsuit for violations of the Securities Exchange Act.
  • Allegations indicate Jasper made false and misleading statements to the market.
  • Insufficient controls over third-party manufacturing have put clinical trials at risk.

Full Press Release Details

LOS ANGELES, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of JSPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: November 30, 2023, to July 3, 2025
DEADLINE: November 18, 2025
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Jasper’s controls over third-party manufacturing was insufficient to ensure its vendors followed all applicable rules and regulations. The Company’s clinical trials were placed at risk due to problems with its manufacturing partners. Based on these facts, Jasper’s public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.
WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
274 White Plains Road, Suite 1
Eastchester, NY 10709

Tags

Frequently Asked Questions

What lawsuit is against Jasper Therapeutics?

A class action lawsuit is filed for violations of the Securities Exchange Act.

What is the deadline for the Jasper lawsuit?

The deadline to file is November 18, 2025.

What period does the class action cover?

It covers the period from November 30, 2023, to July 3, 2025.

How can shareholders participate in the lawsuit?

Shareholders can register and will receive updates with no cost to participate.

What issues did Jasper Therapeutics allegedly face?

The company faced problems with third-party manufacturing, risking clinical trials.

Last updated: Nov 14, 2025